alexa Oral Ribavirin Treatment Failure for Severe Parainfluen
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Oral Ribavirin Treatment Failure for Severe Parainfluenza Type 1 Infection in a Patient with End Stage Interstitial Lung Disease Successfully Treated with DAS181

Bogdanovich T1, Kwak EJ1, Silveira FP1, Pakstis DL1, Lanza P2*, and Moss RB2
1Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA
2Ansun Biopharma, Inc., San Diego, CA, USA
*Corresponding Author : Lanza P
Ansun Biopharma, Inc., 3030 Callan Road
San Diego CA 92121, USA
Tel: 858-452-2631
Fax: 858-452-0133
E-mail: [email protected]
Received: January 27, 2016; Accepted: February 18, 2016; Published: February 28, 2016
Citation: Bogdanovich T, Kwak EJ, Silveira FP, Pakstis DL, Lanza P, et al. (2016) Oral Ribavirin Treatment Failure for Severe Para Influenza Type 1 Infection in a Patient with End Stage Interstitial Lung Disease Successfully Treated with DAS181. J Antivir Antiretrovir 8:020-022. doi:10.4172/jaa.1000130
Copyright: © 2016 Lanza P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Parainfluenza virus (PIV) infections can cause serious respiratory infections and death in immunocompromised patients. No antiviral drugs have proven efficacy against PIV. DAS181, a sialidase fusion protein has been shown to inhibit infection with PIV strains both in vitro and in animal model. The clinical course of immunocompromised patients with PIV-1 infection is described. After being diagnosed with PIV infection, patient was treated for 18 days with oral Ribavirin (RBV) but failed to respond clinically and no virus clearance was obtained. However, patient tested negative for PIV after a 10-days DAS181 treatment course. This case exemplifies failure of oral RBV treatment of severe Parainfluenza virus infection and subsequent viral clearance associated with administration of inhaled DAS181. Large scale randomized trials are warranted to determine the therapeutic efficacy of DAS181 against PIV related lung disease.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords